Core Insights - Insmed Incorporated presented 11 new abstracts at the ATS 2025 International Conference, highlighting the efficacy and safety of brensocatib in treating non-cystic fibrosis bronchiectasis [1][3] - The ASPEN trial demonstrated consistent efficacy across various patient subgroups, reinforcing brensocatib's potential as a foundational treatment for bronchiectasis [2][3] Group 1: Brensocatib and ASPEN Trial Findings - Brensocatib showed a reduction in pulmonary exacerbations and prolonged time to first exacerbation compared to placebo, with a similar safety profile [3][5] - In adolescents aged 12 and older, brensocatib reduced annualized exacerbation rates significantly, with 59% of patients remaining exacerbation-free compared to 35% on placebo [5] - The trial included 391 active sites across 35 countries, with a total of 1,680 adult patients and 41 adolescent patients participating [5][6] Group 2: Additional Research and Data - Insmed presented a post-hoc analysis on the healthcare burden of bronchiectasis and findings from an expanded Phase 2 analysis of TPIP for pulmonary hypertension associated with interstitial lung disease [4] - Real-world outcomes for ARIKAYCE treatment were also shared, demonstrating longitudinal health status improvements in patients with refractory Mycobacterium avium complex lung disease [4] Group 3: Company Overview and Commitment - Insmed is focused on delivering first- and best-in-class therapies for serious diseases, with a diverse portfolio of approved and investigational medicines [29][30] - The company emphasizes its commitment to advancing research that can transform care for patients with serious diseases [3][29]

Core Insights - Insmed Incorporated will present 11 abstracts from its respiratory portfolio at the ATS 2025 International Conference, focusing on the efficacy and safety of brensocatib and health outcomes in patients with Mycobacterium Avium Complex lung disease [1][2][26] Group 1: Company Overview - Insmed is a global biopharmaceutical company dedicated to developing first- and best-in-class therapies for serious diseases [1][26] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [26][27] Group 2: Research and Development - The Phase 3 ASPEN study is the largest clinical trial in bronchiectasis to date, evaluating brensocatib's performance across various patient subgroups [2][6] - New health economics and outcomes research related to MAC lung disease will also be presented, highlighting treatment patterns and health status improvements [1][3] Group 3: Upcoming Presentations - Presentations will include analyses of treatment patterns in non-cystic fibrosis bronchiectasis and healthcare resource utilization for MAC lung disease [3] - Specific sessions will focus on the efficacy of brensocatib in patients with different backgrounds, including those with eosinophilic bronchiectasis [3][9]